Argenx (ARGX) stock pushed higher on Aug. 26 after UBS issued a bullish note in favor of the biotech firm, citing a stronger outlook for its flagship Vyvgart franchise. Analyst Xian Deng upgraded ARGX this morning to “Buy” and raised her price target significantly to $1,400, indicating potential upside of about 37% from current levels.
Note that Argenx shares have already been a blockbuster investment for 2026, currently up more than 50% versus their year-to-date low.